CYP17A1 and metastatic neoplasm: Treatment options for CRPC and patients with metastatic disease at diagnosis include chemotherapy, radium-223, second generation anti-androgens (e.g., the Cytochrome P450 17A1 (CYP17A1) inhibitor abiraterone acetate that prevents androgen biosynthesis, or enzalutamide that targets AR directly), and clinical trials [5,6,8,9,10].